Option chain shows key data for Henkel AG & Co's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Henkel AG & Co.

Henkel AG & Co (OTC:HENKY) Stock, Option Chain

Henkel AG & Co

Two distinct customer groups constitute Henkel. The consumer segment (around 50% of consolidated 2023 sales) is laundry and home care, including the Persil and Purex laundry detergent brands, and beauty care, including the Schwarzkopf brand in hair care and the Dial brand in hand soap. The adhesives technologies segment makes up the remaining 50% of sales. Sales from Europe accounted for 38% of the firm's consolidated total in 2023, while Asia-Pacific and North America accounted for 15% and 28%, respectively.

Earnings

News

Upgrades

Markets

Analyst Ratings

Trading Ideas

HENKY

Henkel AG &amp; Co. (OTC: HENKY) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.

All You Need to Know About Henkel AG &amp; Co. Rating Upgrade to Buy

Short Ideas

On Wednesday, shares of Henkel AG &amp; Co. KGaA (OTC: HENKY) experienced volatile short activity. After the activity, the stock price went up +0.57% to $15.91.

The overall sentiment for HENKY has been Bearish.

Short Volatility Alert: Henkel AG &amp; Co. KGaA

Government

Regulations

AMZN

The Consumer Brands Association, a trade association representing the nation’s leading packaged goods companies, has called on the Biden administration for “immediate clarification” of the COVID-19 vaccine mandate announced last week by the president.

Consumer Brands Association Seeks &#39;Immediate Clarification&#39; From Biden On Vaccine Mandate

HENKEL AG & CO KGAA S/ADR by Henkel AG & Co. KGAA

Henkel AG & Co KGaA

Henkel AG &amp; Co. (OTC: <a class="ticker" href="https://www.benzinga.com/stock/henky#OTC">HENKY</a>) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.
The sole determinant of the Zacks rating is a company&#39;s changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by the system.
Individual investors often find it hard to make decisions based on rating upgrades by Wall Street analysts, since these are mostly driven by subjective factors that are hard to see and measure in real time. In these situations, the Zacks rating system comes in handy because of the power of a changing earnings picture in determining near-term stock price movements.
As such, the Zacks rating upgrade for Henkel AG &amp; Co. is essentially a positive comment on its earnings outlook that could have a favorable impact on its stock price.
Most Powerful Force Impacting Stock Prices
The change in a company&#39;s future earnings potential, as reflected in earnings estimate revisions, and the near-term price movement of its stock are proven to be strongly correlated. The influence of institutional investors has a partial contribution to this relationship, as these big professionals use earnings and earnings estimates to calculate the fair value of a company&#39;s shares. An increase or decrease in earnings estimates in their valuation models simply results in higher or lower fair value for a stock, and institutional investors typically buy or sell it. Their bulk investment action then leads to price movement for the stock.
Fundamentally speaking, rising earnings estimates and the consequent rating upgrade for Henkel AG &amp; Co. imply an improvement in the company&#39;s underlying business. Investors should show their appreciation for this improving business trend by pushing the stock higher.
Harnessing the Power of Earnings Estimate Revisions
As empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock movements, tracking such revisions for making an investment decision could be truly rewarding. Here is where the tried-and-tested Zacks Rank stock-rating system plays an important role, as it effectively harnesses the power of earnings estimate revisions.
The Zacks Rank stock-rating system, which uses four factors related to earnings estimates to classify stocks into five groups, ranging from Zacks Rank #1 (Strong Buy) to Zacks Rank #5 (Strong Sell), has an impressive externally-audited track record, with Zacks Rank #1 stocks generating an average annual return of +25% since 1988.
Earnings Estimate Revisions for Henkel AG &amp; Co.
For the fiscal year ending December 2024, this company is expected to earn $1.27 per share, which is a change of 8.6% from the year-ago reported number.
Analysts have been steadily raising their estimates for Henkel AG &amp; Co. Over the past three months, the Zacks Consensus Estimate for the company has increased 1.2%.
Bottom Line
Unlike the overly optimistic Wall Street analysts whose rating systems tend to be weighted toward favorable recommendations, the Zacks rating system maintains an equal proportion of &#39;buy&#39; and &#39;sell&#39; ratings for its entire universe of more than 4000 stocks at any point in time. Irrespective of market conditions, only the top 5% of the Zacks-covered stocks get a &#39;Strong Buy&#39; rating and the next 15% get a &#39;Buy&#39; rating. So, the placement of a stock in the top 20% of the Zacks-covered stocks indicates its superior earnings estimate revision feature, making it a solid candidate for producing market-beating returns in the near term.
The upgrade of Henkel AG &amp; Co. to a Zacks Rank #2 positions it in the top 20% of the Zacks-covered stocks in terms of estimate revisions, implying that the stock might move higher in the near term.
<a href="https://www.zacks.com/stock/news/2273032/all-you-need-to-know-about-henkel-ag-co-henky-rating-upgrade-to-buy?cid=CS-BENZ-FT-tale_of_the_tape|yseop_template_12_zacks_rank_upgrade-2273032">To read this article on Zacks.com click here.</a>

All You Need to Know About Henkel AG & Co. Rating Upgrade to Buy

On Wednesday, shares of Henkel AG &amp; Co. KGaA (OTC: <a class="ticker" href="https://www.benzinga.com/stock/henky#OTC">HENKY</a>) experienced volatile short activity. After the activity, the stock price went up +0.57% to $15.91.
The overall sentiment for HENKY has been Bearish.
The signal from the volatility alert is trending Bearish. Therefore, the recommendation is to Strong Sell.
The volatility alert was produced on the prior trading date, 8/3/2022 with a volatility change of +350.95%. The current volatility indicator stands at 20.452.&nbsp;
Overview: 
The securities lending volatility indicator is produced by Tidal Markets, in partnership with Benzinga Insights. Securities lending primarily serves the purpose of providing liquidity to short sellers. When unusual activity occurs in the securities lending markets, it acts as an upstream indicator to what is likely to occur downstream in the regular stock market.
Understanding the Volatility Alert: 
Overall sentiment is considered &quot;bear&quot; when broad market activity of the stock has been shown to indicate a negative directional basis, or is considered &quot;bull&quot; when indicating a positive directional basis. The securities lending volatility indicator provides a signal when it detects unusual short activity. Unusual short activity is based off a computer generated algorithmic formula utilizing securities lending trade details such as the volume of shares being shorted, the rate being paid to short the shares, and the type of collateral being posted - amongst other variables. The current volatility is the respective trading day&#39;s calculated securities lending volatility value. The volatility percentage change is the percentage difference in volatility between the two most recent days. The recommendation is a suggestive strategy, inferred from the strength of the Signal Trending, Current Volatility, and Volatility % Change. Recommendations may include, &quot;Strong Buy&quot;, &quot;Strong Sell&quot;, &quot;Increase Short Exposure&quot;, &quot;Decrease Short Exposure&quot;, or &quot;Market Neutral&quot;.
ANY INFORMATION CONTAINED HEREIN DOES NOT CONSTITUTE OR IMPLY INVESTMENT ADVICE 
&nbsp;

Short Volatility Alert: Henkel AG & Co. KGaA

The Consumer Brands Association, a trade association representing the nation&rsquo;s leading packaged goods companies, has called on the Biden administration for &ldquo;immediate clarification&rdquo; of the COVID-19 vaccine mandate announced last week by the president.
What Happened:&nbsp;President Biden announced an executive order that required all private-sector&nbsp;employers with more than 100 employees to either require full vaccinations from&nbsp;their workforce or to begin weekly COVID-19 testing for employees who are not vaccinated.
However, the announcement was made before the mandate was developed.
The U.S. Department of Labor&rsquo;s Occupational Safety and Health Administration is planning to issue an Emergency Temporary Standard to implement this requirement, although no date has been set for its issuance.
In a letter to the administration, CBA President and CEO Geoff Freeman noted that while his organization&rsquo;s membership base &ldquo;supports efforts to vaccinate as many Americans as possible,&rdquo; it has been confused and disappointed with Washington&rsquo;s response to the health crisis.
&ldquo;Throughout the COVID-19 pandemic, the government has often failed to implement well-intentioned policy,&rdquo; Freeman stated &ldquo;President Biden&rsquo;s announcement prompts critical questions that require immediate clarification. As with other mandates, the devil is in the details. Without additional clarification for the business community, employee anxieties and questions will multiply.&rdquo;
Freeman pointed to a survey that found nearly two-thirds of U.S. consumer packaged goods companies had problems with what they considered to be conflicting pandemic guidance from federal, state and local governments.
&ldquo;Across the federal government, we will need to see a degree of coordination, rapid response and private <a href="https://www.benzinga.com/money/best-sectors-to-invest-in-right-now/">sector</a> engagement to be successful,&rdquo; he continued. &ldquo;We look forward to working with the administration to increase vaccination rates of essential workers throughout the country.&rdquo;
Related Link: <a href="https://www.benzinga.com/government/21/08/22657246/most-americans-blame-biden-for-mismanaging-afghanistan-crisis-poll">Most Americans Blame Biden For Mismanaging Afghanistan Crisis: Poll</a>
What Else Happened: The CBA included a long list of questions for the administration that included:
&bull; What is considered documentation for proof of vaccination and how will booster vaccinations be factored into compliance? 
&bull; Must an employee be &ldquo;fully vaccinated&rdquo; in order to work? 
&bull; How will the requirements address natural immunity? Will individuals that have contracted COVID-19 be required to be vaccinated or submit to testing requirements? 
&bull; Does the government have plans to centralize vaccination tracking or is it the responsibility of businesses to manage? 
&bull; Is there a single testing standard that must be met that would be considered compliant to the negative test result requirement? 
&bull; What is considered suitable documentation of a negative test result? 
&bull; If an employee takes a COVID-19 test but the results are not yet available, is the employee allowed to continue to work pending the results? 
&bull; How does this mandate impact locations with collective bargaining and existing collective bargaining agreements? 
&bull; Will this federal requirement preempt existing state-imposed obligations? 
&bull; Do the new federal requirements include exemptions based on sincerely held religious beliefs and disabilities? 
&bull; Will waivers be&nbsp;allowed if essential employee absences or attrition cause significant disruption to the CPG supply chain?
The CBA membership includes Campbell Soup Company NYSE: CPB), Coca-Cola Co&nbsp;(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ko#NYSE">KO</a>), Colgate-Palmolive Company (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/cl#NYSE">CL</a>), Henkel AG&nbsp;&amp; Co&nbsp;(OTC: <a class="ticker" href="https://www.benzinga.com/stock/henky#OTC">HENKY</a>), Molson Coors Beverage Co&nbsp;(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/tap#NYSE">TAP</a>) and Procter &amp; Gamble Co&nbsp;(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/pg#NYSE">PG</a>).
Three major retailers &mdash;&nbsp;Albertsons Companies Inc (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/aci#NYSE">ACI</a>), Amazon.com, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/amzn#NASDAQ">AMZN</a>) and Target Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/tgt#NYSE">TGT</a>) &mdash;&nbsp;are also CBA members.
Photo: Wilfried Pohnke from Pixabay.

Consumer Brands Association Seeks 'Immediate Clarification' From Biden On Vaccine Mandate

&nbsp;
<h2>Upgrades</h2>
<ul>
<li>According to Benchmark, the prior rating for TopBuild Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BLD#NYSE">BLD</a>) was changed from Hold to Buy. In the second quarter, TopBuild showed an EPS of $2.76, compared to $1.68 from the year-ago quarter. At the moment, the stock has a 52-week-high of $235.50 and a 52-week-low of $144.58. TopBuild closed at $219.98 at the end of the last trading period.</li>
<li>For Belden Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BDC#NYSE">BDC</a>), Canaccord Genuity upgraded the previous rating of Hold to Buy. For the second quarter, Belden had an EPS of $1.21, compared to year-ago quarter EPS of $0.46. At the moment, the stock has a 52-week-high of $58.54 and a 52-week-low of $28.55. Belden closed at $56.96 at the end of the last trading period.</li>
<li>For NeoPhotonics Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NPTN#NYSE">NPTN</a>), Raymond James upgraded the previous rating of Underperform to Market Perform. For the second quarter, NeoPhotonics had an EPS of $0.22, compared to year-ago quarter EPS of $0.16. At the moment, the stock has a 52-week-high of $14.14 and a 52-week-low of $5.75. NeoPhotonics closed at $9.39 at the end of the last trading period.</li>
<li>SVB Leerink upgraded the previous rating for HealthEquity Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQY#NASDAQ">HQY</a>) from Market Perform to Outperform. HealthEquity earned $0.40 in the second quarter, compared to $0.42 in the year-ago quarter. The stock has a 52-week-high of $93.32 and a 52-week-low of $45.82. At the end of the last trading period, HealthEquity closed at $63.18.</li>
<li>For Biomarin Pharmaceutical Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMRN#NASDAQ">BMRN</a>), Stifel upgraded the previous rating of Hold to Buy. In the second quarter, Biomarin Pharmaceutical showed an EPS of $0.07, compared to $0.16 from the year-ago quarter. At the moment, the stock has a 52-week-high of $92.56 and a 52-week-low of $71.35. Biomarin Pharmaceutical closed at $76.70 at the end of the last trading period.</li>
<li>Stifel upgraded the previous rating for AppLovin Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APP#NASDAQ">APP</a>) from Hold to Buy. AppLovin earned $0.04 in the second quarter, compared to $0.10 in the year-ago quarter. At the moment, the stock has a 52-week-high of $90.03 and a 52-week-low of $49.41. AppLovin closed at $68.00 at the end of the last trading period.</li>
<li>According to Jefferies, the prior rating for Banco Santander SA (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SAN#NYSE">SAN</a>) was changed from Underperform to Hold. Banco Santander earned $0.13 in the second quarter. At the moment, the stock has a 52-week-high of $4.38 and a 52-week-low of $1.78. Banco Santander closed at $3.61 at the end of the last trading period.</li>
</ul>
<a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">See all analyst ratings upgrades.</a>
&nbsp;
<h2>Downgrades</h2>
<ul>
<li>JP Morgan downgraded the previous rating for Humanigen Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HGEN#NASDAQ">HGEN</a>) from Neutral to Underweight. In the second quarter, Humanigen showed an EPS of $1.20, compared to $0.79 from the year-ago quarter. At the moment, the stock has a 52-week-high of $29.20 and a 52-week-low of $7.50. Humanigen closed at $15.11 at the end of the last trading period.</li>
<li>According to Macquarie, the prior rating for Score Media and Gaming Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCR#NASDAQ">SCR</a>) was changed from Outperform to Neutral. In the third quarter, Score Media and Gaming earned $0.63. The stock has a 52-week-high of $36.32 and a 52-week-low of $12.95. At the end of the last trading period, Score Media and Gaming closed at $35.46.</li>
<li>According to Citigroup, the prior rating for Sherwin-Williams Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHW#NYSE">SHW</a>) was changed from Buy to Neutral. Sherwin-Williams earned $2.65 in the second quarter, compared to $7.10 in the year-ago quarter. At the moment, the stock has a 52-week-high of $768.00 and a 52-week-low of $244.67. Sherwin-Williams closed at $296.69 at the end of the last trading period.</li>
<li>According to Citigroup, the prior rating for Axalta Coating Systems Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AXTA#NYSE">AXTA</a>) was changed from Buy to Neutral. Axalta Coating Sys earned $0.48 in the second quarter, compared to $0.15 in the year-ago quarter. At the moment, the stock has a 52-week-high of $34.20 and a 52-week-low of $21.43. Axalta Coating Sys closed at $29.07 at the end of the last trading period.</li>
<li>According to Citigroup, the prior rating for PPG Industries Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PPG#NYSE">PPG</a>) was changed from Buy to Neutral. In the second quarter, PPG Industries showed an EPS of $1.94, compared to $0.99 from the year-ago quarter. The current stock performance of PPG Industries shows a 52-week-high of $182.97 and a 52-week-low of $116.95. Moreover, at the end of the last trading period, the closing price was at $151.02.</li>
<li>Mizuho downgraded the previous rating for Eversource Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ES#NYSE">ES</a>) from Neutral to Underperform. In the second quarter, Eversource Energy showed an EPS of $0.79, compared to $0.76 from the year-ago quarter. The stock has a 52-week-high of $96.66 and a 52-week-low of $76.64. At the end of the last trading period, Eversource Energy closed at $91.89.</li>
<li>For Vertex Pharmaceuticals Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>), Stifel downgraded the previous rating of Buy to Hold. Vertex Pharmaceuticals earned $3.11 in the second quarter, compared to $2.61 in the year-ago quarter. The current stock performance of Vertex Pharmaceuticals shows a 52-week-high of $280.99 and a 52-week-low of $185.32. Moreover, at the end of the last trading period, the closing price was at $191.37.</li>
<li>Morgan Stanley downgraded the previous rating for Cisco Systems Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSCO#NASDAQ">CSCO</a>) from Overweight to Equal-Weight. For the fourth quarter, Cisco Systems had an EPS of $0.84, compared to year-ago quarter EPS of $0.80. The current stock performance of Cisco Systems shows a 52-week-high of $60.27 and a 52-week-low of $35.28. Moreover, at the end of the last trading period, the closing price was at $58.68.</li>
<li>For Kadmon Holdings Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KDMN#NASDAQ">KDMN</a>), Jefferies downgraded the previous rating of Buy to Hold. Kadmon Holdings earned $0.18 in the second quarter, compared to $0.17 in the year-ago quarter. At the moment, the stock has a 52-week-high of $9.20 and a 52-week-low of $3.15. Kadmon Holdings closed at $9.07 at the end of the last trading period.</li>
</ul>
<a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">See all analyst ratings downgrades.</a>
&nbsp;
<h2>Initiations</h2>
<ul>
<li>JP Morgan initiated coverage on Westport Fuel Systems Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WPRT#NASDAQ">WPRT</a>) with a Neutral rating. The price target for Westport Fuel Systems is set to $5.00. For the second quarter, Westport Fuel Systems had an EPS of $0.11, compared to year-ago quarter EPS of $0.02. The stock has a 52-week-high of $12.95 and a 52-week-low of $1.55. At the end of the last trading period, Westport Fuel Systems closed at $3.67.</li>
<li>Citigroup initiated coverage on Lucid Group Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LCID#NASDAQ">LCID</a>) with a Buy rating. The price target for Lucid Gr is set to $28.00. &nbsp;Moreover, at the end of the last trading period, the closing price was at $18.93.</li>
<li>UBS initiated coverage on Zogenix Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZGNX#NASDAQ">ZGNX</a>) with a Buy rating. The price target for Zogenix is set to $23.00. In the second quarter, Zogenix showed an EPS of $1.05, compared to $0.96 from the year-ago quarter. At the moment, the stock has a 52-week-high of $25.31 and a 52-week-low of $13.01. Zogenix closed at $14.60 at the end of the last trading period.</li>
<li>Stephens &amp; Co. initiated coverage on Apollo Endosurgery Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APEN#NASDAQ">APEN</a>) with an Overweight rating. The price target for Apollo Endosurgery is set to $15.00. In the second quarter, Apollo Endosurgery showed an EPS of $0.22, compared to $0.30 from the year-ago quarter. The stock has a 52-week-high of $10.00 and a 52-week-low of $1.25. At the end of the last trading period, Apollo Endosurgery closed at $9.64.</li>
<li>With a Neutral rating, Arete Research initiated coverage on Discovery Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DISCA#NASDAQ">DISCA</a>). The price target seems to have been set at $30.00 for Discovery. Discovery earned $0.92 in the second quarter, compared to $0.77 in the year-ago quarter. At the moment, the stock has a 52-week-high of $78.14 and a 52-week-low of $19.07. Discovery closed at $26.98 at the end of the last trading period.</li>
<li>With a Buy rating, Arete Research initiated coverage on The Walt Disney Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIS#NYSE">DIS</a>). The price target seems to have been set at $263.00 for Walt Disney. Walt Disney earned $0.80 in the third quarter, compared to $0.08 in the year-ago quarter. The stock has a 52-week-high of $203.02 and a 52-week-low of $117.23. At the end of the last trading period, Walt Disney closed at $185.15.</li>
<li>With a Buy rating, Arete Research initiated coverage on Netflix Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>). The price target seems to have been set at $735.00 for Netflix. For the second quarter, Netflix had an EPS of $2.97, compared to year-ago quarter EPS of $1.59. The current stock performance of Netflix shows a 52-week-high of $615.60 and a 52-week-low of $458.60. Moreover, at the end of the last trading period, the closing price was at $606.05.</li>
<li>HSBC initiated coverage on Kimberly-Clark Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KMB#NYSE">KMB</a>) with a Hold rating. The price target for Kimberly-Clark is set to $131.00. For the second quarter, Kimberly-Clark had an EPS of $1.47, compared to year-ago quarter EPS of $2.20. The stock has a 52-week-high of $155.45 and a 52-week-low of $128.02. At the end of the last trading period, Kimberly-Clark closed at $141.49.</li>
<li>Needham initiated coverage on Upwork Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPWK#NASDAQ">UPWK</a>) with a Buy rating. The price target for Upwork is set to $57.00. Upwork earned $0.03 in the second quarter, compared to $0.09 in the year-ago quarter. The stock has a 52-week-high of $64.49 and a 52-week-low of $13.46. At the end of the last trading period, Upwork closed at $43.98.</li>
<li>With a Buy rating, B of A Securities initiated coverage on Arvinas Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARVN#NASDAQ">ARVN</a>). The price target seems to have been set at $110.00 for Arvinas. In the second quarter, Arvinas showed an EPS of $1.03, compared to $0.65 from the year-ago quarter. At the moment, the stock has a 52-week-high of $108.47 and a 52-week-low of $19.68. Arvinas closed at $91.88 at the end of the last trading period.</li>
<li>SVB Leerink initiated coverage on Myovant Sciences Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MYOV#NYSE">MYOV</a>) with a Market Perform rating. The price target for Myovant Sciences is set to $24.00. Myovant Sciences earned $0.67 in the first quarter, compared to $0.37 in the year-ago quarter. The current stock performance of Myovant Sciences shows a 52-week-high of $30.90 and a 52-week-low of $13.42. Moreover, at the end of the last trading period, the closing price was at $25.81.</li>
<li>With a Market Perform rating, SVB Leerink initiated coverage on scPharmaceuticals Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCPH#NASDAQ">SCPH</a>). The price target seems to have been set at $6.00 for scPharmaceuticals. In the second quarter, scPharmaceuticals showed an EPS of $0.26, compared to $0.36 from the year-ago quarter. At the moment, the stock has a 52-week-high of $9.64 and a 52-week-low of $4.75. scPharmaceuticals closed at $5.95 at the end of the last trading period.</li>
<li>Credit Suisse initiated coverage on SoFi Technologies Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOFI#NASDAQ">SOFI</a>) with a Neutral rating. The price target for SoFi Technologies is set to $16.50. SoFi Technologies earned $0.48 in the second quarter, compared to $0.03 in the year-ago quarter. The current stock performance of SoFi Technologies shows a 52-week-high of $24.95 and a 52-week-low of $13.56. Moreover, at the end of the last trading period, the closing price was at $15.47.</li>
<li>MKM Partners initiated coverage on Denbury Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DEN#NYSE">DEN</a>) with a Buy rating. The price target for Denbury is set to $96.00. Denbury earned $0.61 in the second quarter, compared to $0.07 in the year-ago quarter. At the moment, the stock has a 52-week-high of $81.37 and a 52-week-low of $15.43. Denbury closed at $70.06 at the end of the last trading period.</li>
<li>With an Overweight rating, JP Morgan initiated coverage on Blade Air Mobility Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLDE#NASDAQ">BLDE</a>). The price target seems to have been set at $16.00 for Blade Air Mobility. Blade Air Mobility earned $0.15 in the third quarter. At the moment, the stock has a 52-week-high of $11.87 and a 52-week-low of $6.41. Blade Air Mobility closed at $8.79 at the end of the last trading period.</li>
</ul>
<a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">See all analyst ratings initiations.</a>

Downgrades

Initiation

Intraday Update

ALGS

AMRN

APEN

ARVN

AVIR

AXTA

BDRFY

BLDE

BMRN

BYSI

BZZUY

CFRX

CSCO

DISCA

ENTA

GSHD

HGEN

HLLY

HYZN

IFSUF

KDMN

LBRT

LCID

LESL

MYOV

NFLX

NPTN

ONXXF

ORGN

PDRDY

RKLB

RKLY

SCPH

SOFI

UPWK

VOSSY

VRTX

WPRT

ZGNX

Benzinga's Top Ratings Upgrades, Downgrades For September 9, 2021

Goldman Sachs analyst Olivier Nicolai downgrades Henkel AG &amp; Co (OTC:<a class="ticker" href="https://www.benzinga.com/stock/HENKY#OTC">HENKY</a>) from Buy to Neutral.

Goldman Sachs Downgrades Henkel AG & Co to Neutral

&nbsp;
<h2>Upgrades</h2>
<ul>
<li>For Okta Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OKTA#NASDAQ">OKTA</a>), Needham upgraded the previous rating of Hold to Buy. In the second quarter, Okta showed an EPS of $0.11, compared to $0.07 from the year-ago quarter. The stock has a 52-week-high of $294.00 and a 52-week-low of $185.05. At the end of the last trading period, Okta closed at $264.76.</li>
<li>According to JP Morgan, the prior rating for UCB SA (OTC:<a class="ticker" href="https://www.benzinga.com/stock/UCBJY#OTC">UCBJY</a>) was changed from Neutral to Overweight. The stock has a 52-week-high of $59.86 and a 52-week-low of $44.41. At the end of the last trading period, UCB closed at $57.52.</li>
</ul>
<a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">See all analyst ratings upgrades.</a>
&nbsp;
<h2>Downgrades</h2>
<ul>
<li>Janney Montgomery Scott downgraded the previous rating for Texas Capital Bancshares Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCBI#NASDAQ">TCBI</a>) from Buy to Neutral. In the second quarter, Texas Capital Bancshares showed an EPS of $1.31, compared to $0.26 from the year-ago quarter. At the moment, the stock has a 52-week-high of $93.26 and a 52-week-low of $29.45. Texas Capital Bancshares closed at $67.10 at the end of the last trading period.</li>
<li>According to B of A Securities, the prior rating for Alkermes PLC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALKS#NASDAQ">ALKS</a>) was changed from Neutral to Underperform. In the second quarter, Alkermes showed an EPS of $0.30, compared to $0.06 from the year-ago quarter. At the moment, the stock has a 52-week-high of $31.52 and a 52-week-low of $15.35. Alkermes closed at $31.25 at the end of the last trading period.</li>
<li>According to William Blair, the prior rating for Assembly Biosciences Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASMB#NASDAQ">ASMB</a>) was changed from Outperform to Market Perform. In the second quarter, Assembly Biosciences showed an EPS of $0.55, compared to $0.19 from the year-ago quarter. The current stock performance of Assembly Biosciences shows a 52-week-high of $21.93 and a 52-week-low of $3.32. Moreover, at the end of the last trading period, the closing price was at $3.90.</li>
</ul>
<a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">See all analyst ratings downgrades.</a>
&nbsp;
<h2>Initiations</h2>
<ul>
<li>With a Buy rating, Craig-Hallum initiated coverage on Teradata Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDC#NYSE">TDC</a>). The price target seems to have been set at $88.00 for Teradata. For the second quarter, Teradata had an EPS of $0.74, compared to year-ago quarter EPS of $0.24. The stock has a 52-week-high of $59.58 and a 52-week-low of $17.99. At the end of the last trading period, Teradata closed at $54.66.</li>
<li>With a Buy rating, B. Riley Securities initiated coverage on RumbleON Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RMBL#NASDAQ">RMBL</a>). The price target seems to have been set at $70.00 for RumbleON. In the second quarter, RumbleON showed an EPS of $1.05, compared to $1.79 from the year-ago quarter. The current stock performance of RumbleON shows a 52-week-high of $64.13 and a 52-week-low of $25.38. Moreover, at the end of the last trading period, the closing price was at $36.44.</li>
<li>B. Riley Securities initiated coverage on Portage Biotech Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTG#NASDAQ">PRTG</a>) with a Buy rating. The price target for Portage Biotech is set to $40.00. Portage Biotech earned $0.25 in the first quarter. At the moment, the stock has a 52-week-high of $44.98 and a 52-week-low of $13.40. Portage Biotech closed at $21.61 at the end of the last trading period.</li>
<li>Cantor Fitzgerald initiated coverage on Regulus Therapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGLS#NASDAQ">RGLS</a>) with an Overweight rating. The price target for Regulus Therapeutics is set to $2.00. In the second quarter, Regulus Therapeutics showed an EPS of $0.08, compared to $0.23 from the year-ago quarter. At the moment, the stock has a 52-week-high of $2.32 and a 52-week-low of $0.42. Regulus Therapeutics closed at $0.81 at the end of the last trading period.</li>
<li>With a Buy rating, Deutsche Bank initiated coverage on Blade Air Mobility Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLDE#NASDAQ">BLDE</a>). The price target seems to have been set at $15.00 for Blade Air Mobility. In the third quarter, Blade Air Mobility earned $0.15. At the moment, the stock has a 52-week-high of $11.87 and a 52-week-low of $6.41. Blade Air Mobility closed at $8.85 at the end of the last trading period.</li>
<li>With a Hold rating, Deutsche Bank initiated coverage on Starbucks Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBUX#NASDAQ">SBUX</a>). The price target seems to have been set at $127.00 for Starbucks. In the third quarter, Starbucks showed an EPS of $1.01, compared to $0.46 from the year-ago quarter. The current stock performance of Starbucks shows a 52-week-high of $126.32 and a 52-week-low of $81.75. Moreover, at the end of the last trading period, the closing price was at $117.45.</li>
<li>With an Outperform rating, Baird initiated coverage on RumbleON Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RMBL#NASDAQ">RMBL</a>). The price target seems to have been set at $42.00 for RumbleON. For the second quarter, RumbleON had an EPS of $1.05, compared to year-ago quarter EPS of $1.79. The current stock performance of RumbleON shows a 52-week-high of $64.13 and a 52-week-low of $25.38. Moreover, at the end of the last trading period, the closing price was at $36.44.</li>
<li>With an Outperform rating, Wedbush initiated coverage on Catabasis Pharmaceuticals Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CATB#NASDAQ">CATB</a>). The price target seems to have been set at $16.00 for Catabasis Pharmaceuticals. In the second quarter, Catabasis Pharmaceuticals showed an EPS of $0.89, compared to $0.53 from the year-ago quarter. The current stock performance of Catabasis Pharmaceuticals shows a 52-week-high of $10.19 and a 52-week-low of $1.20. Moreover, at the end of the last trading period, the closing price was at $9.41.</li>
<li>Stifel initiated coverage on Materialise NV (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTLS#NASDAQ">MTLS</a>) with a Buy rating. The price target for Materialise is set to $30.00. For the second quarter, Materialise had an EPS of $0.07, compared to year-ago quarter EPS of $0.04. The stock has a 52-week-high of $87.40 and a 52-week-low of $18.52. At the end of the last trading period, Materialise closed at $22.91.</li>
<li>Goldman Sachs initiated coverage on Enviva Partners LP (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVA#NYSE">EVA</a>) with a Neutral rating. The price target for Enviva Partners is set to $54.00. In the second quarter, Enviva Partners showed an EPS of $0.24, compared to $0.26 from the year-ago quarter. At the moment, the stock has a 52-week-high of $56.69 and a 52-week-low of $36.57. Enviva Partners closed at $53.83 at the end of the last trading period.</li>
</ul>
<a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">See all analyst ratings initiations.</a>

ALKS

ASMB

CATB

FMCXF

MAPS

MTLS

OKTA

PRTG

RGLS

RMBL

SBUX

TCBI

UCBJY

VLTA

Benzinga's Top Ratings Upgrades, Downgrades For September 2, 2021

JP Morgan analyst Celine Pannuti downgrades Henkel AG &amp; Co (OTC:<a class="ticker" href="https://www.benzinga.com/stock/HENKY#OTC">HENKY</a>) from Overweight to Neutral.

Comments

Henkel AG & Co

Henkel AG & Co (HENKY) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga